October 6th, 2011

J&J Pleads Guilty, Pays $85 Million to Settle Natrecor Case

The U.S. Department of Justice announced that Johnson & Johnson has pleaded guilty to a misdemeanor and has agreed to pay an $85 million criminal fine to settle charges about the company’s marketing of Natrecor (nesiritide) for off-label use.

The government said that Scios, the J&J subsidiary that marketed the drug, “admitted that it intended Natrecor to be used off-label for infusing chronic (non-acute) CHF patients on a scheduled, serial basis and that it understood that this was not an approved use of the drug.”

Comments are closed.